Holen Sie sich die Stockscreener-App
55.15
1.87%
1.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$54.14
Offen:
$54.655
24-Stunden-Volumen:
6.59M
Relative Volume:
2.81
Marktkapitalisierung:
$5.13B
Einnahmen:
$536.20M
Nettoeinkommen (Verlust:
$-45.64M
KGV:
-103.12
EPS:
-0.5348
Netto-Cashflow:
$-28.94M
1W Leistung:
+12.76%
1M Leistung:
+28.58%
6M Leistung:
+59.90%
1J Leistung:
+282.72%
1-Tages-Spanne:
$53.75
$55.99
1-Wochen-Bereich:
$48.98
$55.99
52-Wochen-Spanne:
$13.97
$55.99
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
55.15 | 5.13B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
TVTX Maintained by Evercore ISI Group -- Price Target Raised to $60 - GuruFocus
Travere Therapeutics Inc (TVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Travere Therapeutics Inc (TVTX) Institutional Confidence - TradingKey
Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Travere Therapeutics Inc (TVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TVTX) Movement - Stock Traders Daily
Travere Therapeutics Inc (TVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Travere Therapeutics stock hits 52-week high at 54.49 USD By Investing.com - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 54.49 USD - Investing.com
Travere Therapeutics, Inc. (TVTX) latest stock news and headlines - Yahoo Finance Singapore
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Travere therapeutics director sells $225,000 of TVTX shares - Investing.com UK
Travere therapeutics director Timothy Coughlin sells $500,747 in stock - Investing.com
Travere Therapeutics announces retirement of chief research officer and new leadership appointments - Investing.com UK
Travere therapeutics director sells $225,000 of TVTX shares By Investing.com - Investing.com UK
Travere Therapeutics announces leadership changes in R&D - Investing.com
Travere Therapeutics (TVTX) Announces Leadership Change in Research Division - GuruFocus
Travere Therapeutics announces leadership changes in R&D By Investing.com - Investing.com Canada
Travere Therapeutics Chief Research Officer William Rote to Retire - marketscreener.com
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) details CRO retirement and elevates CMO to lead R&D - Stock Titan
Travere Therapeutics Announces Planned Retirement Of Chief Research Officer In 2027 - TradingView
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 - Business Wire
Travere Therapeutics Is Maintained at Buy by Citigroup - Moomoo
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
TVTX Maintained by Citigroup -- Price Target Raised to $70.00 - GuruFocus
Travere Therapeutics price target raised to $70 from $62 at Citi - TipRanks
TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? - Insider Monkey
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $65 - GuruFocus
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Roy Baynes to sell 4,500 TVTX shares via option exercise (TVTX) - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 reports 3,250-share sale - Stock Titan
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20 - Investor's Business Daily
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Travere Therapeutics stock hits 52-week high at 48.7 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 48.7 USD - Investing.com
3 Stocks That May Be Priced Below Their Estimated Value In June 2026 - simplywall.st
Transcript : Travere Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 11 - marketscreener.com
Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Discipline and Rules-Based Execution in TVTX Response - Stock Traders Daily
Travere therapeutics CCO sells $101,417 in stock for tax obligations - Investing.com
Travere therapeutics chief research officer Rote sells $121,433 in shares - Investing.com
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines - MSN
Travere buys BTK inhibitor for $1.1bn to treat kidney disease - BioXconomy
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion - ANTARA News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines - BioPharma APAC
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):